Form 4: GE HealthCare Technologies Inc. Executive Acquires Shares and Stock Options

Philip Rackliffe, CEO of AVS at GE HealthCare Technologies Inc., reports acquisition of shares and stock options.

Summary

• On March 3, 2025, Philip Rackliffe, CEO of AVS at GE HealthCare Technologies Inc., acquired 4,916 shares of common stock.
• Rackliffe also disposed of 17,473 shares of common stock.
• Additionally, Rackliffe was awarded 14,058 employee stock options with an exercise price of $86.45.
• These options become exercisable in three tranches starting September 3, 2026.
• Rackliffe directly owns 14,058 derivative securities following the reported transaction.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document primarily reports transactions without expressing an opinion on the company's performance or future prospects. The acquisition is balanced by the disposal of shares.

Positives

• The acquisition of stock options by a key executive could be seen as a positive signal, indicating confidence in the company's future performance.

Negatives

• The disposal of 17,473 shares by the same executive could be interpreted negatively, although the overall context and reasons for the sale are not provided.

Risks

• The vesting of the stock options and restricted stock units is subject to certain conditions, which are not specified in the document, introducing some uncertainty.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules for the stock options and restricted stock units suggest a long-term incentive structure for the executive.

Industry Context

Executive compensation and insider trading activity are closely monitored in the healthcare technology industry to ensure alignment of management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a common component of executive compensation packages in large publicly traded companies like GE HealthCare.
• The vesting schedules (33%, 33%, 34% over three years) are fairly standard compared to companies like Siemens Healthineers or Philips, which often use similar vesting periods to incentivize long-term performance.
• The exercise price of $86.45 would need to be compared to the market price of GE HealthCare stock at the time of the grant to assess its competitiveness.
• Similar filings for executives at comparable companies (e.g., Medtronic, Abbott) would provide a benchmark for the size and structure of the equity grants.

Stakeholder Impact

• The transactions may influence shareholder perception of management's confidence in the company.
• Employees may view the stock option grants as a positive sign of potential future gains.

Key Dates